ALX-0600 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	2

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00308438 (ClinicalTrials.gov)	March 1, 2004	13/9/2005	Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008	An Open Label Extension Study of the Safety and Efficacy of ALX-0600 in Subjects With Crohn's Disease Who Completed the Pilot Study Protocol CL0600-008	Crohn's Disease	Drug: Teduglutide (ALX-0600)	Shire	NULL	Completed	18 Years	N/A	All	67	Phase 2	United States;Canada
2	NCT00072839 (ClinicalTrials.gov)	November 12, 2003	11/11/2003	Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease	A Pilot Study of the Safety and Efficacy of ALX-0600 in Subjects With Moderately Active Crohn's Disease	Crohn's Disease	Drug: ALX-0600;Drug: placebo;Drug: teduglutide 0.05;Drug: teduglutide 0.2 mg;Drug: Teduglutide 0.05 dose;Drug: teduglutide 0.1 mg dose	Shire	NULL	Completed	18 Years	N/A	All	100	Phase 2	United States;Canada